期刊文献+

RRM1、BRCA1表达与非小细胞肺癌关系研究进展

RESEARCH PROGRESS ON THE RELATIONSHIP BETWEEN RRM1、BRCA1 EXPRESSION AND NON SMALL CELL LUNG CANCER
下载PDF
导出
摘要 非小细胞肺癌的标准化疗方案为含铂的两联疗法,治疗后的肿瘤缓解情况存在明显的个体差异。肿瘤细胞对抗癌药物的敏感性与其自身DNA的损伤修复能力密切相关。 The standard chemotherapy for non-small cell lung cancer is platinum contained of two combination therapy. After treatment of tumor remission obvious individual differences, the ability to repair the damaged sensitivity of tumor cells to anticancer drugs and DNA are closely related.
出处 《内蒙古医科大学学报》 2016年第6期580-584,共5页 Journal of Inner Mongolia Medical University
基金 内蒙古科技厅自然基金(2013MS1140)
关键词 非小细胞肺癌 核苷酸还原酶M1 乳腺癌易感基因1 non-small-cell lung cancer
  • 相关文献

参考文献5

二级参考文献60

  • 1龚伟华,孙月华,朱振安,史定伟,唐坚.分期微创治疗胫腓骨开放性骨折[J].临床骨科杂志,2005,8(1):10-13. 被引量:22
  • 2欧阳国新,汤志辉,李铭.单侧外固定支架治疗胫腓骨骨折的体会[J].临床骨科杂志,2007,10(1):84-85. 被引量:10
  • 3吴雪晖,李起鸿,许建中,杨柳,王序全,李建福.骨外固定技术不植骨治疗复杂性骨不连与骨缺损[J].中华创伤杂志,2007,23(6):407-411. 被引量:15
  • 4[1]Danzinger S,Filipits M.Biomarkers the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC).Wien Med Wochenschr,2007,157(21-22):554-561.
  • 5[2]Rosell R,Felip E,Paz-Ares L.How could pharmacogenomics help improve patient survival.Lung Cancer,2007,57(Suppl 2):35-41.
  • 6[3]Simon G,Sharma A,Li X,et al.Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced nun-small-cell lung cancer.J Clin Oncol,2007,25(19):2741-2746.
  • 7[4]Song PF,Li S,Meibohm B,et al.Detection of MDRI single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction:MDR1 single nucleotide polymorphism genotyping.Assay AAPS Pharm Sci,2002,4(4):1-6.
  • 8[5]Bepler G,Zhong Zh,Gautam A,et al.Ribonucleotide reductase M1 gane promoter activity polymorphisms,population frequencies and clinical relevance.Lung cancer,2005,47(2):183-192.
  • 9[6]Taron M,Alberola V,Sanchcz JJ,et al.Transcription-coupled repair(TCR) XPD and RRM1 gene polymorphisms predict gemcitabine (gem)/cisplatin (cis) outcome in non-small-cell lung cancer (NSCLC).2003 ASCO Annual Meeting (Abstr 2579).
  • 10[7]Cardenal F,Ramir ez JL,Taron M,et al.XPD and RRM1 gene polymorphisms predict gemcitabine (gem)/cisplatin (cis)/docetaxel (doc)outcome in stage Ⅲ non-small-cell lung cancer (NSCLC):A genetic analysis of the Spanish Lung Cancer Group phase Ⅱ trial 9901.2003 ASCO Annual Meeting (Abstr 2612).

共引文献90

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部